Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Headache, Maternal exposure during pregnancy, Pain in extremity, Tachycardia
Clinical narrative: Tachycardia; Shortness of breath; Arm soreness; Headache; Redness around injection site; Small bumps around the injection site; Pregnancy; This spontaneous prospective pregnancy case was reported by an other health care professional and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy), TACHYCARDIA (Tachycardia), DYSPNOEA (Shortness of breath), PAIN IN EXTREMITY (Arm soreness) and HEADACHE (Headache) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025L20A and 020M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included IRON and ASCORBIC ACID, FERROUS FUMARATE, FOLIC ACID, RETINOL (PRENATAL [ASCORBIC ACID;FERROUS FUMARATE;FOLIC ACID;RETINOL]) for an unknown indication.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was in June 2020 and the estimated date of delivery was 01-Apr-2021. On 05-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy). On 06-Jan-2021, the patient experienced TACHYCARDIA (Tachycardia), DYSPNOEA (Shortness of breath), PAIN IN EXTREMITY (Arm soreness), HEADACHE (Headache), VACCINATION SITE ERYTHEMA (Redness around injection site) and VACCINATION SITE RASH (Small bumps around the injection site). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  The patient was treated with BUTALBITAL, CAFFEINE, PARACETAMOL (BUTALBITAL, ACETAMINOPHEN & CAFFEINE) for Headache, at an unspecified dose and frequency. At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy), TACHYCARDIA (Tachycardia), DYSPNOEA (Shortness of breath), HEADACHE (Headache), VACCINATION SITE ERYTHEMA (Redness around injection site) and VACCINATION SITE RASH (Small bumps around the injection site) outcome was unknown and PAIN IN EXTREMITY (Arm soreness) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications also included Butalbital-Acetaminophen-Caffeine for unknown indication.  Treatment medication Butalbital-Acetaminophen-Caffeine was taken after the second dose.; Sender's Comments: This case concerns a 30 year-old, female patient, who experienced an event of exposure during pregnancy after receiving her first and second dose of mRNA-1273 vaccine.  In addition, the patient experienced arm soreness, headache, shortness of breath, tachycardia, redness around injection site, and small bumps around the injection site after her first dose of mRNA-1273 and experienced headache after her second dose. Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.